Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.
1. Candel appointed Dr. Carl H. June to its Research Advisory Board. 2. Dr. June is an expert in cancer immunotherapy with notable achievements. 3. Candel’s leading candidates, CAN-2409 and CAN-3110, advancing in clinical trials. 4. Anticipated BLA submission for CAN-2409 in prostate cancer by Q4 2026. 5. Recent successes in trials boost Candel's potential market position.